Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

NCT01729806 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

CD20 Positive
Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Rituximab

Sponsor

National Cancer Institute (NCI)